FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570262483> ?p ?o ?g. }

• W2570262483 endingPage "S1262" @default.
• W2570262483 startingPage "S1261" @default.
• W2570262483 abstract "Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), was approved in May 2016 in Japan. Its administration requires a tumor rebiopsy to detect the EGFR T790M mutation. AURA and AURA2 studies with 411 patients demonstrated a remarkable clinical outcome with an overall response rate (ORR) of around 65% and progression-free survival (PFS) of 9.7 months. Several authors reported that the detection rate of T790M by tumor rebiopsy in these patients was approximately 52 to 68%. However, thorough accumulation of data is required to establish the clinical relevance of T790M detection and osimertinib response. We retrospectively reviewed the clinical courses of NSCLC patients with the EGFR mutation, who had undergone rebiopsies and osimertinib therapy. Eleven patients with the EGFR mutation (exon19del [n=10] and L858R [n=1]) were included. Average age was 67 years old (range 53–79). The following EGFR-TKIs were administered to the 11 patients before rebiopsy; elrotinib (n=6), afatinib (n=5) and gefitinib (n=2). The patients received rebiopsy in the 2nd line treatment (n=3), 3rd line (n=2), 5th line (n=2), 6th line (n=2) and 7th line (n=2). Rebiopsy sites were primary lung tumors (n=8), supraclavicular lymph node (n=1), liver metastasis (n=1) and pleural effusion (1). Among them, T790M was detected in four, zero, one, and one, respectively (detection rate: 54.5%). Rebiopsy was successfully performed in all patients, among whom one required a second attempt. ASP8273, another third-generation EGFR-TKI, and osimertinib were administered in one and two patients, respectively. The remaining two patients are to be treated with osimertinib. Both patients who received osimertinib achieved partial response, and their ECOG performance status (PS) was remarkably improved from 4 to 1, and 3 to 1. One of the two patients experienced grade 4 neutropenia; thus, the osimertinib dose was reduced from 80 mg to 40 mg daily. The remaining patient suffered from erythema; however, it was improved after ten-day cessation of medication. Osimertinib was then resumed at 80 mg daily with no severe side effects experienced thereafter. The detection rate of T790M by rebiopsy was consistent with previous reports. Osimertinib was feasible and effective for our patients with poor PS; however, a prospective study is required to confirm osimertinib’s validity for such patients. In WCLC 2016, we will increase the number of patients who undergo rebiopsy and osimertinib therapy, and we hope to demonstrate detailed detection patterns of T790M, as well as ORR and PFS." @default.
• W2570262483 created "2017-01-13" @default.
• W2570262483 creator A5006699400 @default.
• W2570262483 creator A5007143858 @default.
• W2570262483 creator A5010575912 @default.
• W2570262483 creator A5025321734 @default.
• W2570262483 creator A5039150667 @default.
• W2570262483 creator A5043717227 @default.
• W2570262483 creator A5047702281 @default.
• W2570262483 creator A5053056759 @default.
• W2570262483 creator A5073197092 @default.
• W2570262483 creator A5087435965 @default.
• W2570262483 date "2017-01-01" @default.
• W2570262483 modified "2023-09-29" @default.
• W2570262483 title "P3.02b-113 Clinical Course of NSCLC Patients with EGFR Mutation Undergoing Rebiopsy and Osimertinib Therapy" @default.
• W2570262483 doi "https://doi.org/10.1016/j.jtho.2016.11.1781" @default.
• W2570262483 hasPublicationYear "2017" @default.
• W2570262483 type Work @default.
• W2570262483 sameAs 2570262483 @default.
• W2570262483 citedByCount "1" @default.
• W2570262483 countsByYear W25702624832017 @default.
• W2570262483 crossrefType "journal-article" @default.
• W2570262483 hasAuthorship W2570262483A5006699400 @default.
• W2570262483 hasAuthorship W2570262483A5007143858 @default.
• W2570262483 hasAuthorship W2570262483A5010575912 @default.
• W2570262483 hasAuthorship W2570262483A5025321734 @default.
• W2570262483 hasAuthorship W2570262483A5039150667 @default.
• W2570262483 hasAuthorship W2570262483A5043717227 @default.
• W2570262483 hasAuthorship W2570262483A5047702281 @default.
• W2570262483 hasAuthorship W2570262483A5053056759 @default.
• W2570262483 hasAuthorship W2570262483A5073197092 @default.
• W2570262483 hasAuthorship W2570262483A5087435965 @default.
• W2570262483 hasBestOaLocation W25702624831 @default.
• W2570262483 hasConcept C121608353 @default.
• W2570262483 hasConcept C126322002 @default.
• W2570262483 hasConcept C143998085 @default.
• W2570262483 hasConcept C2776256026 @default.
• W2570262483 hasConcept C2777626846 @default.
• W2570262483 hasConcept C2777930144 @default.
• W2570262483 hasConcept C2778087573 @default.
• W2570262483 hasConcept C2779438470 @default.
• W2570262483 hasConcept C2780580887 @default.
• W2570262483 hasConcept C2780586478 @default.
• W2570262483 hasConcept C71924100 @default.
• W2570262483 hasConceptScore W2570262483C121608353 @default.
• W2570262483 hasConceptScore W2570262483C126322002 @default.
• W2570262483 hasConceptScore W2570262483C143998085 @default.
• W2570262483 hasConceptScore W2570262483C2776256026 @default.
• W2570262483 hasConceptScore W2570262483C2777626846 @default.
• W2570262483 hasConceptScore W2570262483C2777930144 @default.
• W2570262483 hasConceptScore W2570262483C2778087573 @default.
• W2570262483 hasConceptScore W2570262483C2779438470 @default.
• W2570262483 hasConceptScore W2570262483C2780580887 @default.
• W2570262483 hasConceptScore W2570262483C2780586478 @default.
• W2570262483 hasConceptScore W2570262483C71924100 @default.
• W2570262483 hasIssue "1" @default.
• W2570262483 hasLocation W25702624831 @default.
• W2570262483 hasOpenAccess W2570262483 @default.
• W2570262483 hasPrimaryLocation W25702624831 @default.
• W2570262483 hasRelatedWork W2762724643 @default.
• W2570262483 hasRelatedWork W2822334320 @default.
• W2570262483 hasRelatedWork W2921871143 @default.
• W2570262483 hasRelatedWork W2972277738 @default.
• W2570262483 hasRelatedWork W3000070469 @default.
• W2570262483 hasRelatedWork W3036162643 @default.
• W2570262483 hasRelatedWork W3169621419 @default.
• W2570262483 hasRelatedWork W3175282903 @default.
• W2570262483 hasRelatedWork W4281670385 @default.
• W2570262483 hasRelatedWork W4281690819 @default.
• W2570262483 hasVolume "12" @default.
• W2570262483 isParatext "false" @default.
• W2570262483 isRetracted "false" @default.
• W2570262483 magId "2570262483" @default.
• W2570262483 workType "article" @default.